Systematic review of factors affecting pharmaceutical expenditures
To systematically identify the main factors contributing to the increase in pharmaceutical expenditures.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Schneeweiss, Sebastian, 2007. "Reference drug programs: Effectiveness and policy implications," Health Policy, Elsevier, vol. 81(1), pages 17-28, April.
- Daniella Perlroth & Dana Goldman & Alan Garber, 2010. "The potential impact of comparative effectiveness research on U.S. Health Care expenditures," Demography, Springer, vol. 47(1), pages S173-S190, March.
- Donald Vandegrift & Anusua Datta, 2006. "Prescription Drug Expenditures in the United States: The Effects of Obesity, Demographics, and New Pharmaceutical Products," Southern Economic Journal, Southern Economic Association, vol. 73(2), pages 515–529, October.
- Owen F. Humpage, 2008. "Rising relative prices or inflation: why knowing the difference matters," Economic Commentary, Federal Reserve Bank of Cleveland, issue Jun.
- Michael Dickson & Heinz Redwood, 1998. "Pharmaceutical Reference Prices: How do They Work in Practice?," PharmacoEconomics, Springer Healthcare | Adis, vol. 14(5), pages 471-479.
- Philippe Cavalié, 2003. "Is therapeutic innovation responsible for the increase in drug expenditure?," The European Journal of Health Economics, Springer, vol. 4(3), pages 184-194, September.
- Hanley, Gillian E. & Morgan, Steve, 2009. "Chronic catastrophes: Exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada," Social Science & Medicine, Elsevier, vol. 68(5), pages 919-924, March.
- Ulf-G. Gerdtham & Magnus Johannesson & Bo Gunnarsson & Margareta Marcusson & Freddie Henriksson, 1998. "The Effect of Changes in Treatment Patterns on Drug Expenditure," PharmacoEconomics, Springer Healthcare | Adis, vol. 13(1 Part 2), pages 127-134.
- Giuliani, Giovanni & Selke, Gisbert & Garattini, Livio, 1998. "The German experience in reference pricing," Health Policy, Elsevier, vol. 44(1), pages 73-85, April.
- Noyce, Peter R. & Huttin, Christine & Atella, Vicenzo & Brenner, Gerhard & Haaijer-Ruskamp, Flora M. & Hedvall, Maj-Britt & Mechtler, Reli, 2000. "The cost of prescription medicines to patients," Health Policy, Elsevier, vol. 52(2), pages 129-145, June.
- Ulf-G Gerdtham & Magnus Johannesson & Bo Gunnarsson & Margareta Marcusson & Freddie Henriksson, 1998. "Price Indices of Drugs and the Switching to New Drugs: Two Empirical Examples," PharmacoEconomics, Springer Healthcare | Adis, vol. 13(1 Part 1), pages 71-80.
- Morgan, Steven G. & Agnew, Jonathan D. & Barer, Morris L., 2004. "Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia," Health Policy, Elsevier, vol. 68(3), pages 299-307, June.
- Silvia M. Ess & Sebastian Schneeweiss & Thomas D. Szucs, 2003. "European Healthcare Policies for Controlling Drug Expenditure," PharmacoEconomics, Springer Healthcare | Adis, vol. 21(2), pages 89-103.
- Anirban Basu & Tomas J. Philipson, 2010.
"The Impact of Comparative Effectiveness Research on Health and Health Care Spending,"
NBER Working Papers
15633, National Bureau of Economic Research, Inc.
- Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011. "The impact of comparative effectiveness research on health and health care spending," Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.
- Burstall, Michael L., 1997. "The management of the cost and utilisation of pharmaceuticals in the United Kingdom," Health Policy, Elsevier, vol. 41(Supplemen), pages S27-S43, September.
- Ljungkvist, Mats-Olof & Andersson, David & Gunnarsson, Bo, 1997. "Cost and utilisation of pharmaceuticals in Sweden," Health Policy, Elsevier, vol. 41(Supplemen), pages S55-S69, September.
- Lisa L. Ioannides-Demos & Joseph E. Ibrahim & John J. McNeil, 2002. "Reference-Based Pricing Schemes: Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes," PharmacoEconomics, Springer Healthcare | Adis, vol. 20(9), pages 577-591.
- Bong-Min Yang, 2009. "The Future of Health Technology Assessment in Healthcare Decision Making in Asia," PharmacoEconomics, Springer Healthcare | Adis, vol. 27(11), pages 891-901.
- Ulf-G. Gerdtham & Douglas Lundin, 2004. "Why Did Drug Spending Increase During the 1990s?: A Decomposition Based on Swedish Data," PharmacoEconomics, Springer Healthcare | Adis, vol. 22(1), pages 29-42.
- Van Tielen, Rudy & Peys, Frank & Genaert, Jean, 1998. "The demographic impact on ambulatory pharmaceutical expenditure in Belgium," Health Policy, Elsevier, vol. 45(1), pages 1-14, July.
- Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:116:y:2014:i:2:p:137-146. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Zhang, Lei)or () The email address of this maintainer does not seem to be valid anymore. Please ask to update the entry or send us the correct address
If references are entirely missing, you can add them using this form.